136 related articles for article (PubMed ID: 7629426)
21. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer.
Lyubimova NV; Pashkov MV; Tyulyandin SA; Gol'dberg VE; Kushlinskii NE
Bull Exp Biol Med; 2004 Jul; 138(1):77-9. PubMed ID: 15514730
[TBL] [Abstract][Full Text] [Related]
22. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism.
Stĕpán JJ; Mikulecký M; Bek V; Broulík P; Pacovský V
Neoplasma; 1989; 36(4):495-501. PubMed ID: 2770935
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.
Garnero P; Delmas PD
J Clin Endocrinol Metab; 1993 Oct; 77(4):1046-53. PubMed ID: 8104954
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of current techniques in detecting and monitoring bone metastases from breast cancer.
Parbhoo SP
J R Soc Med; 1985; 78 Suppl 9(Suppl 9):7-10. PubMed ID: 3876441
[No Abstract] [Full Text] [Related]
25. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
26. CA 15-3 and bone scintigraphy in the follow-up of breast cancer.
Younsi N; Montravers F; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Int J Biol Markers; 1997; 12(4):154-7. PubMed ID: 9582604
[TBL] [Abstract][Full Text] [Related]
27. [Clinical application of alkaline phosphatase bone-isoenzyme determination with acetate foil].
Lanzer G; Leb G
Acta Med Austriaca; 1983; 10(2-3):61-6. PubMed ID: 6576551
[TBL] [Abstract][Full Text] [Related]
28. [Immunoradiometric assay of tumor marker CA15-3 and its clinical application].
Chen Z; Fan Z; Yang J
Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):125-8. PubMed ID: 10920962
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
[TBL] [Abstract][Full Text] [Related]
30. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of bone markers for detection of bone metastases in lung cancer patients.
Alataş F; Alataş O; Metintaş M; Colak O; Erginel S; Harmanci E
Clin Biochem; 2002 Jun; 35(4):293-6. PubMed ID: 12135691
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of bone formation markers in breast cancer.
Palma MA; Body JJ
Int J Biol Markers; 2005; 20(3):146-55. PubMed ID: 16240842
[TBL] [Abstract][Full Text] [Related]
33. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.
Koizumi M; Matsumoto S; Takahashi S; Yamashita T; Ogata E
Clin Nucl Med; 1999 Jan; 24(1):15-20. PubMed ID: 9890487
[TBL] [Abstract][Full Text] [Related]
34. Serum alkaline phosphatase isoenzyme activities in canine malignant mammary neoplasms with and without osseous transformation.
Karayannopoulou M; Polizopoulou ZS; Koutinas AF; Fytianou A; Roubies N; Kaldrymidou E; Tsioli V; Patsikas MN; Constantinidis TC; Koutinas CK
Vet Clin Pathol; 2006 Sep; 35(3):287-90. PubMed ID: 16967410
[TBL] [Abstract][Full Text] [Related]
35. Biochemical markers for detecting bone metastases in patients with breast cancer.
Moro L; Gazzarrini C; Crivellari D; Galligioni E; Talamini R; de Bernard B
Clin Chem; 1993 Jan; 39(1):131-4. PubMed ID: 8419037
[TBL] [Abstract][Full Text] [Related]
36. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?
Buffaz PD; Gauchez AS; Caravel JP; Vuillez JP; Cura C; Agnius-Delord C; Fagret D
Eur J Nucl Med; 1999 Jan; 26(1):8-11. PubMed ID: 9933655
[TBL] [Abstract][Full Text] [Related]
37. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients.
Chao TY; Ho CL; Lee SH; Chen MM; Janckila A; Yam LT
J Biomed Sci; 2004; 11(4):511-6. PubMed ID: 15153786
[TBL] [Abstract][Full Text] [Related]
38. Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer.
Francini G; Montagnani M; Petrioli R; Paffetti P; Marsili S; Leone V
Int J Biol Markers; 1990; 5(2):65-72. PubMed ID: 2283479
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer.
Capeller B; Caffier H; Sütterlin MW; Dietl J
Anticancer Res; 2003; 23(2A):1011-5. PubMed ID: 12820340
[TBL] [Abstract][Full Text] [Related]
40. Comparison of assay of total and bone-specific alkaline phosphatase in the assessment of osteoblast activity in patients with metastatic bone disease.
Piovesan A; Berruti A; Torta M; Cannone R; Sperone P; Panero A; Gorzegno G; Termine A; Dogliotti L; Angeli A
Calcif Tissue Int; 1997 Nov; 61(5):362-9. PubMed ID: 9351876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
